PT  - JOURNAL ARTICLE
AU  - De-Leon, Hilla
AU  - Aran, Dvir
TI  - What pushed Israel out of herd immunity? Modeling COVID-19 spread of Delta and Waning immunity
AID  - 10.1101/2021.09.12.21263451
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.12.21263451
4099  - http://medrxiv.org/content/early/2021/09/20/2021.09.12.21263451.short
4100  - http://medrxiv.org/content/early/2021/09/20/2021.09.12.21263451.full
AB  - Following a successful vaccination campaign at the beginning of 2021 in Israel, where approximately 60% of the population were vaccinated with an mRNA BNT162b2 vaccine, it seemed that Israel had crossed the herd immunity threshold (HIT). Nonetheless, Israel has seen a steady rise in COVID-19 morbidity since June 2021, reaching over 1,000 cases per million by August. This outbreak is attributed to several events that came together: the temporal decline of the vaccine’s effectiveness (VE); lower effectiveness of the vaccine against the current Delta (B.1.617.2) variant; highly infectiousness of Delta; and temporary halt of mandated NPIs (non-pharmaceutical interventions) or any combination of the above. Using a novel spatial-dynamic model and recent aggregate data from Israel, we examine the extent of the impact of the Delta variant on morbidity and whether it can solely explain the outbreak. We conclude that both Delta infectiousness and waning immunity could have been able to push Israel below the HIT independently, and thus, to mitigate the outbreak effective NPIs are required. Our analysis cautions countries that once vaccines’ will wane a highly infectious spread is expected, and therefore, the expected decline in the vaccine’s effectiveness in those countries should be accompanied by another vaccination campaign and effective NPIs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDA is supported by the Azrieli Faculty Fellowship and is a Deloro FellowAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the data is available onlineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data in available on: 1.https://datadashboard.health.gov.il/COVID-19/general 2. https://github.com/dancarmoz/israel_moh_covid_dashboard_data 3. https://ourworldindata.org/coronavirus https://ourworldindata.org/coronavirus https://data.gov.il/dataset/covid-19 https://github.com/dancarmoz/israel_moh_covid_dashboard_data